Darshan Arora, MD
Nephrology · Troy, NYNPI 1316934383
Payments from drug & device makers
Across 478 payments — averaging $20.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Mallinckrodt Hospital Products Inc.$1K
- Amgen$936
- Bayer$876
- Otsuka America Pharmaceutical, Inc.$825
- GSK$578
- plus $4K from 26 others
What the payments were for
- Food & beverage$9,38194%
- Education$5826%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 87 | $1,598 |
| Mallinckrodt Hospital Products Inc. | 37 | $1,074 |
| Amgen(2 entities) | 42 | $936 |
| Bayer | 38 | $876 |
| Otsuka America Pharmaceutical, Inc. | 43 | $825 |
| GSK | 33 | $578 |
| Vifor Pharma, Inc. | 29 | $563 |
| OPKO Pharmaceuticals, LLC | 19 | $370 |
| Calliditas Therapeutics US Inc. | 14 | $331 |
| Travere Therapeutics, Inc. | 14 | $318 |
| Fresenius USA Marketing, Inc. | 20 | $276 |
| Aurinia Pharma U.S., Inc. | 11 | $240 |
| Novo Nordisk | 11 | $232 |
| Boehringer Ingelheim | 10 | $219 |
| Sanofi | 9 | $203 |
| Akebia Therapeutics Inc | 10 | $203 |
| Novartis | 6 | $166 |
| Arbor Pharmaceuticals, Inc. | 9 | $153 |
| Ardelyx, Inc. | 1 | $123 |
| Renalytix AI, Inc. | 7 | $114 |
| Lilly USA, LLC | 4 | $101 |
| Lundbeck LLC | 4 | $84 |
| Daiichi Sankyo Inc. | 4 | $62 |
| Johnson & Johnson | 4 | $62 |
| Alnylam Pharmaceuticals Inc. | 3 | $55 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $38 |
| Ultragenyx Pharmaceutical Inc. | 2 | $36 |
| ANI Pharmaceuticals, Inc. | 1 | $35 |
| Boston Scientific | 1 | $23 |
| Leadiant Biosciences, Inc. | 1 | $22 |
| Pharmacosmos Therapeutics Inc. | 1 | $22 |
| Mallinckrodt Enterprises LLC | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TERLIVAZ$129
- Tavneos$123
- XPHOZAH 30 MG$123
- LOKELMA$104
How this compares
$9,963 in reported general payments places this provider in the 80th percentile of 935 nephrology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 257 | $275,862 |
| KerendiaFinerenone | 150 | $203,621 |
| JardianceEmpagliflozin | 108 | $142,104 |
| VelphoroSucroferric Oxyhydroxide | 24 | $70,377 |
| JanuviaSitagliptin Phosphate | 37 | $50,767 |
| AuryxiaFerric Citrate | 19 | $38,371 |
| LokelmaSodium Zirconium Cyclosilicate | 31 | $31,558 |
| TrulicityDulaglutide | 20 | $30,308 |
| OzempicSemaglutide | 12 | $26,237 |
| MounjaroTirzepatide | 15 | $22,776 |
| Sevelamer Carbonate | 99 | $19,369 |
| TradjentaLinagliptin | 11 | $15,755 |
| Lanthanum Carbonate | 13 | $14,323 |
| VeltassaPatiromer Calcium Sorbitex | 15 | $12,234 |
| Febuxostat | 36 | $6,289 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $1,598 | $307,420288 claims |
| BayerKerendia | $876 | $203,621150 claims |
| Boehringer IngelheimJardiance, Tradjenta | $219 | $157,859119 claims |
| Fresenius USA Marketing, Inc.Velphoro | $276 | $70,37724 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $101 | $53,08435 claims |
| Akebia Therapeutics IncAuryxia | $203 | $38,37119 claims |
| Novo NordiskOzempic | $232 | $26,23712 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $35 | $2,38898 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 935 nephrology providers in New York.
Other nephrology in Troy
- Joseph RoglieriTroy$425K
- Joji TokitaNew York$8.4M
- Krzysztof KirylukNew York$6.7M
- David BernardNew York$6M
- Andrew BombackNew York$3.4M
- Pietro CanettaNew York$3.2M
- Robert LynnBronx$2M
- Jodumutt BhatMaspeth$1.5M
- Gerald AppelNew York$1.5M
- David CharytanNew York$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.